These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22154350)

  • 1. Discovery of bacterial NAD⁺-dependent DNA ligase inhibitors: improvements in clearance of adenosine series.
    Stokes SS; Gowravaram M; Huynh H; Lu M; Mullen GB; Chen B; Albert R; O'Shea TJ; Rooney MT; Hu H; Newman JV; Mills SD
    Bioorg Med Chem Lett; 2012 Jan; 22(1):85-9. PubMed ID: 22154350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity.
    Stokes SS; Huynh H; Gowravaram M; Albert R; Cavero-Tomas M; Chen B; Harang J; Loch JT; Lu M; Mullen GB; Zhao S; Liu CF; Mills SD
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4556-60. PubMed ID: 21719282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds.
    Jahić H; Liu CF; Thresher J; Livchak S; Wang H; Ehmann DE
    Biochem Pharmacol; 2012 Sep; 84(5):654-60. PubMed ID: 22743594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases.
    Meier TI; Yan D; Peery RB; McAllister KA; Zook C; Peng SB; Zhao G
    FEBS J; 2008 Nov; 275(21):5258-71. PubMed ID: 18795946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides.
    Gu W; Wang T; Maltais F; Ledford B; Kennedy J; Wei Y; Gross CH; Parsons J; Duncan L; Arends SJ; Moody C; Perola E; Green J; Charifson PS
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3693-8. PubMed ID: 22560473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity.
    Surivet JP; Lange R; Hubschwerlen C; Keck W; Specklin JL; Ritz D; Bur D; Locher H; Seiler P; Strasser DS; Prade L; Kohl C; Schmitt C; Chapoux G; Ilhan E; Ekambaram N; Athanasiou A; Knezevic A; Sabato D; Chambovey A; Gaertner M; Enderlin M; Boehme M; Sippel V; Wyss P
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6705-11. PubMed ID: 23006603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Optimization of NAD+-Dependent DNA Ligase Inhibitors as Novel Antibacterial Compounds.
    Bi F; Ma R; Ma S
    Curr Pharm Des; 2017; 23(14):2117-2130. PubMed ID: 27784238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-amino-pyrido[2,3-d]pyrimidin-5(8H)-ones.
    Wang T; Duncan L; Gu W; O'Dowd H; Wei Y; Perola E; Parsons J; Gross CH; Moody CS; Arends SJ; Charifson PS
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3699-703. PubMed ID: 22560470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations.
    Murphy-Benenato K; Wang H; McGuire HM; Davis HE; Gao N; Prince DB; Jahic H; Stokes SS; Boriack-Sjodin PA
    Bioorg Med Chem Lett; 2014 Jan; 24(1):360-6. PubMed ID: 24287382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Base-modified NAD and AMP derivatives and their activity against bacterial DNA ligases.
    Pergolizzi G; Cominetti MM; Butt JN; Field RA; Bowater RP; Wagner GK
    Org Biomol Chem; 2015 Jun; 13(22):6380-98. PubMed ID: 25974621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I.
    Srivastava SK; Dube D; Tewari N; Dwivedi N; Tripathi RP; Ramachandran R
    Nucleic Acids Res; 2005; 33(22):7090-101. PubMed ID: 16361267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-throughput fluorescence resonance energy transfer-based assay for DNA ligase.
    Shapiro AB; Eakin AE; Walkup GK; Rivin O
    J Biomol Screen; 2011 Jun; 16(5):486-93. PubMed ID: 21398623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor.
    Srivastava SK; Dube D; Kukshal V; Jha AK; Hajela K; Ramachandran R
    Proteins; 2007 Oct; 69(1):97-111. PubMed ID: 17557328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis. Crystal structure of the adenylation domain and identification of novel inhibitors.
    Srivastava SK; Tripathi RP; Ramachandran R
    J Biol Chem; 2005 Aug; 280(34):30273-81. PubMed ID: 15901723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negishi cross-coupling enabled synthesis of novel NAD(+)-dependent DNA ligase inhibitors and SAR development.
    Murphy-Benenato KE; Gingipalli L; Boriack-Sjodin PA; Martinez-Botella G; Carcanague D; Eyermann CJ; Gowravaram M; Harang J; Hale MR; Ioannidis G; Jahic H; Johnstone M; Kutschke A; Laganas VA; Loch JT; Miller MD; Oguto H; Patel SJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5172-7. PubMed ID: 26463129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors.
    Khandekar SS; Feng B; Yi T; Chen S; Laping N; Bramson N
    J Biomol Screen; 2005 Aug; 10(5):447-55. PubMed ID: 16093554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase.
    Montgomery JI; Toogood PL; Hutchings KM; Liu J; Narasimhan L; Braden T; Dermyer MR; Kulynych AD; Smith YD; Warmus JS; Taylor C
    Bioorg Med Chem Lett; 2009 Feb; 19(3):665-9. PubMed ID: 19121937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput assay for the adenylation reaction of bacterial DNA ligase.
    Miesel L; Kravec C; Xin AT; McMonagle P; Ma S; Pichardo J; Feld B; Barrabee E; Palermo R
    Anal Biochem; 2007 Jul; 366(1):9-17. PubMed ID: 17493575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAD(+)-dependent DNA ligase: a novel target waiting for the right inhibitor.
    Dwivedi N; Dube D; Pandey J; Singh B; Kukshal V; Ramachandran R; Tripathi RP
    Med Res Rev; 2008 Jul; 28(4):545-68. PubMed ID: 18080330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.